PlumX Metrics
Embed PlumX Metrics

Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives

Acta Pharmaceutica Sinica B, ISSN: 2211-3835, Vol: 13, Issue: 4, Page: 1467-1487
2023
  • 13
    Citations
  • 0
    Usage
  • 16
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Researchers at University of Macau Have Published New Data on Cancer (Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives)

2023 MAY 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- Data detailed on cancer have been presented. According to

Review Description

Described as a “don't eat me” signal, CD47 becomes a vital immune checkpoint in cancer. Its interaction with signal regulatory protein alpha (SIRP α ) prevents macrophage phagocytosis. In recent years, a growing body of evidences have unveiled that CD47-based combination therapy exhibits a superior anti-cancer effect. Latest clinical trials about CD47 have adopted the regimen of collaborating with other therapies or developing CD47-directed bispecific antibodies, indicating the combination strategy as a general trend of the future. In this review, clinical and preclinical cases about the current combination strategies targeting CD47 are collected, their underlying mechanisms of action are discussed, and ideas from future perspectives are shared.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know